Efficacy

Lynparza (Olaparib) Efficacy in Breast Cancer

Lynparza, also known by its generic name olaparib, is a medication primarily used as a targeted therapy for certain types of breast cancer. It is a poly (ADP-ribose) polymerase (PARP) inhibitor, which means it works by interfering with the DNA repair process in cancer cells, leading to their death. Specifically, Lynparza has shown efficacy in patients with germline BRCA-mutated, HER2-negative metastatic breast cancer. The effectiveness of Lynparza in treating this subset of breast cancer patients was demonstrated in the OlympiAD trial, a phase III randomized study that showed a statistically significant improvement in progression-free survival compared to standard chemotherapy in patients with BRCA-mutated breast cancer.

In the study, the median progression-free survival for patients treated with Lynparza was significantly longer than for those who received chemotherapy. Additionally, the response rate, which measures the percentage of patients whose cancer shrinks or disappears after treatment, was higher in the Lynparza group. These results support the use of Lynparza as an effective treatment option for patients with BRCA-mutated, HER2-negative metastatic breast cancer, providing a targeted therapy that can lead to better outcomes for these patients.

Enhertu (Fam-Trastuzumab Deruxtecan-nxki) Efficacy in Breast Cancer

Enhertu, with the active ingredient fam-trastuzumab deruxtecan-nxki, is a novel antibody-drug conjugate used for the treatment of HER2-positive breast cancer. Enhertu is designed to deliver chemotherapy directly to cancer cells that overexpress HER2, a protein that promotes the growth of cancer cells. The efficacy of Enhertu in breast cancer treatment was highlighted in the DESTINY-Breast01 trial, a pivotal phase II study that evaluated its use in patients with HER2-positive, unresectable and/or metastatic breast cancer who had previously received two or more anti-HER2 therapies.

The results from the DESTINY-Breast01 trial demonstrated a significant improvement in overall response rate and progression-free survival for patients treated with Enhertu. The treatment was found to be effective in patients who had previously been treated with other HER2-targeted therapies, including trastuzumab and pertuzumab. The data showed that Enhertu provided a new treatment avenue for patients with advanced HER2-positive breast cancer, offering hope for those who had exhausted other treatment options. The promising results from this study led to the accelerated approval of Enhertu by regulatory agencies for this specific patient population.